(Reuters) – The U.S. Food and Drug Administration said a panel of experts would discuss a marketing application from Eli Lilly & Co on a new targeted lung cancer treatment. The FDA said the panel would review data that showed improved overall survival rate in lung cancer patients treated with a combination of Lilly’s experimental drug, necitumumab, and chemotherapy agents gemcitabine and cisplatin. The panel will discuss the application on July 9, FDA said on its website on Tuesday.